tiprankstipranks
Trending News
More News >
WELL Health Technologies Corp (TSE:WELL)
TSX:WELL
Advertisement

WELL Health Technologies Corp (WELL) AI Stock Analysis

Compare
2,245 Followers

Top Page

TSE:WELL

WELL Health Technologies Corp

(TSX:WELL)

Select Model
Select Model
Select Model
Neutral 43 (OpenAI - 4o)
Rating:43Neutral
Price Target:
C$4.50
▲(0.00% Upside)
WELL Health Technologies Corp's overall stock score is primarily impacted by its financial performance, which shows strong revenue growth but significant challenges in profitability and cash flow management. Technical analysis indicates a bearish trend with oversold conditions, while the valuation reflects negative profitability. The absence of earnings call data and corporate events means these factors do not influence the score.
Positive Factors
Revenue Growth
Consistent revenue growth indicates strong market demand and effective business strategies, supporting long-term expansion and market presence.
Business Model
A diversified revenue model enhances resilience against market fluctuations, ensuring stable income and supporting sustainable growth.
Market Position
Strong positioning in digital health provides competitive advantages, aligning with industry trends towards technology-driven healthcare solutions.
Negative Factors
Profitability Challenges
Ongoing profitability issues can hinder reinvestment and growth, potentially impacting long-term financial health and shareholder value.
Cash Flow Management
Negative cash flow can limit operational flexibility and investment capacity, posing risks to sustaining business operations and growth.
Return on Equity
Inability to generate shareholder returns may affect investor confidence and reduce the attractiveness of the company as an investment.

WELL Health Technologies Corp (WELL) vs. iShares MSCI Canada ETF (EWC)

WELL Health Technologies Corp Business Overview & Revenue Model

Company DescriptionWELL Health Technologies Corp. operates as a practitioner focused digital health company in Canada, the United States, and internationally. It offers end-to-end omni-channel patient services, including primary care; physiotherapy, occupational therapy, chiropractic, dietary, mental health counselling, and sleep related services; specialized care, including gastroenterologists; diagnostic services related to cardiology, women's health, and bone/muscle health and cancer diagnostics; and telehealth services. The company also operates OSCAR Pro, an electronic medical records platform; telehealth platforms, including Tia Health, VirtualClinic+, VirtuelMed, Adracare, and Circle Medical; Apps.health, a digital health app marketplace; Insig, which offers virtual care and digital patient engagement services; billing and revenue cycle management solutions for billing and back-office services comprising billing-as-a-service outsourcing services to doctors; and cybersecurity protection and patient data privacy solutions. As of December 31, 2021, the company operated 30 primary care and executive care clinics; and provides primary care, specialty care, and accredited diagnostic health services through 49 locations across Ontario. The company was formerly known as Wellness Lifestyles Inc. and changed its name to WELL Health Technologies Corp. in July 2018. WELL Health Technologies Corp. was incorporated in 2010 and is headquartered in Vancouver, Canada.
How the Company Makes MoneyWELL Health generates revenue through multiple streams, primarily by providing software and technology solutions to healthcare providers. Key revenue sources include subscription fees for its EMR systems, transaction fees from telehealth consultations, and sales of patient engagement tools. Additionally, WELL benefits from partnerships with various healthcare organizations and institutions, which enable it to expand its service offerings and reach a broader customer base. The company also explores opportunities in acquisitions to enhance its technology portfolio and increase market share, contributing to its overall earnings.

WELL Health Technologies Corp Earnings Call Summary

Earnings Call Date:Nov 06, 2025
(Q3-2024)
|
% Change Since: |
Next Earnings Date:Mar 25, 2026
Earnings Call Sentiment Positive
The earnings call was positive overall, with record-setting performances in revenue, EBITDA, and patient visits. Despite challenges like unrealized losses on investments and weather-related impacts, WELL Health's strategic initiatives and strong M&A pipeline position the company for continued growth.
Q3-2024 Updates
Positive Updates
Record Quarterly Performance
The third quarter of 2024 was one of the best in WELL Health's history, with record performances in revenue, adjusted EBITDA, free cash flow, patient visits, and organic growth.
Surpassed $1 Billion Revenue Run Rate
WELL Health surpassed $1 billion in annualized revenue run rate, one quarter ahead of schedule, representing a 30-fold increase over five years.
Strong Revenue and EBITDA Growth
Robust revenue growth of 35% in Canadian patient services and 23% overall organic growth, with adjusted EBITDA of $32.7 million reflecting 16% year-over-year growth.
Record Free Cash Flow
Adjusted free cash flow to shareholders increased by 69% year-over-year and 85% quarter-over-quarter, reaching $0.065 per share.
Significant Debt Reduction
Paid down significant debt, improving leverage ratio to approximately 2.5 from 2.67 in the previous quarter.
Record Patient Visits
Achieved a record 1.5 million patient visits in Q3 2024, a 41% year-over-year increase, with 31% organic growth.
Increased Revenue Guidance
Raised 2024 annual revenue guidance to between $985 million and $995 million.
Strong M&A Pipeline
17 LOIs and deals pending closure, representing over $100 million in annual revenue.
Circle Medical and Wisp Growth
Circle Medical's revenue increased by 61% year-over-year with adjusted EBITDA of $2.6 million, and Wisp achieved record revenue and adjusted EBITDA growth.
Negative Updates
Unrealized Loss on HEALWELL AI Investment
Reported an IFRS net loss of $75.8 million in Q3 2024, primarily due to unrealized losses on WELL's investment in HEALWELL AI.
Impact of Hurricanes
Hurricanes Helen and Milton impacted CRH's revenue, resulting in a minimal revenue loss of approximately CAD 500,000 and an additional $1 to $1.5 million in Q4.
Delayed Billing and Cash Collections
CRH experienced delays in billing and cash collections due to a cybersecurity incident at its billing partner, Change Healthcare.
Company Guidance
In the Q3 2024 earnings call, WELL Health Technologies Corp. provided guidance that highlights several key performance metrics. The company reported record quarterly revenue of $251.7 million, a 23% year-over-year increase driven by 23% organic growth. Adjusted EBITDA reached $32.7 million, reflecting a 16% growth, while adjusted free cash flow to shareholders rose by 69% compared to Q3 2023. WELL surpassed a $1 billion annualized revenue run rate, achieving this milestone one quarter ahead of schedule. The company also increased its annual revenue guidance to between $985 million and $995 million, attributing the rise to recent clinic acquisitions and robust organic growth. Despite revenue growth, annual adjusted EBITDA guidance remains in the upper half of $125 million to $130 million. Additionally, WELL's leverage ratio improved to approximately 2.5, and the company expects its adjusted free cash flow available to shareholders to be around $55 million for 2024. The strategy includes continued strong execution across all business units, with a focus on enhanced profitability, capital efficiency, and organic growth.

WELL Health Technologies Corp Financial Statement Overview

Summary
WELL Health Technologies Corp shows strong revenue growth but struggles with profitability and cash flow management. The balance sheet is stable, but negative profitability and cash flow conversion issues need addressing.
Income Statement
WELL Health Technologies Corp has shown a positive revenue growth rate of 11.56% in the TTM, indicating a strong upward trajectory in sales. However, the company is struggling with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin has decreased over time, reflecting potential cost management issues.
Balance Sheet
The company's debt-to-equity ratio is moderate at 0.57, suggesting a balanced approach to leveraging. However, the negative return on equity in the TTM indicates challenges in generating returns for shareholders. The equity ratio is stable, showing a solid capital structure.
Cash Flow
The cash flow statement reveals a significant improvement in free cash flow growth rate, but the free cash flow remains negative. The operating cash flow to net income ratio is low, indicating potential issues in converting income into cash. The free cash flow to net income ratio is also negative, highlighting cash flow challenges.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.10B919.69M776.05M569.14M302.32M50.24M
Gross Profit429.62M363.01M372.27M303.29M153.69M21.22M
EBITDA-19.20M122.52M101.88M95.99M21.27M-495.00K
Net Income-128.62M32.61M82.00K19.07M-30.69M-2.62M
Balance Sheet
Total Assets2.02B1.81B1.41B1.32B1.26B262.73M
Cash, Cash Equivalents and Short-Term Investments98.89M131.67M43.42M48.91M61.92M86.89M
Total Debt569.76M425.09M426.28M358.42M401.94M23.57M
Total Liabilities1.03B877.55M563.16M503.78M554.37M43.75M
Stockholders Equity826.20M867.61M767.67M732.34M618.24M217.37M
Cash Flow
Free Cash Flow-17.33M-6.70M37.20M70.14M19.59M-6.52M
Operating Cash Flow3.93M9.52M66.44M76.55M22.27M-5.38M
Investing Cash Flow-86.18M-60.23M-106.42M-37.93M-499.78M-44.21M
Financing Cash Flow133.09M133.50M10.63M-52.85M452.53M120.84M

WELL Health Technologies Corp Technical Analysis

Technical Analysis Sentiment
Negative
Last Price4.50
Price Trends
50DMA
5.02
Negative
100DMA
4.78
Negative
200DMA
4.82
Negative
Market Momentum
MACD
-0.06
Positive
RSI
33.64
Neutral
STOCH
6.24
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:WELL, the sentiment is Negative. The current price of 4.5 is below the 20-day moving average (MA) of 5.08, below the 50-day MA of 5.02, and below the 200-day MA of 4.82, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 33.64 is Neutral, neither overbought nor oversold. The STOCH value of 6.24 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:WELL.

WELL Health Technologies Corp Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
C$2.17B-46.32-2.58%0.69%9.94%35.48%
63
Neutral
C$259.74M2.0341.13%2.47%-35.35%948.72%
56
Neutral
C$229.69M3,650.000.11%0.54%0.19%
55
Neutral
C$26.19M157.890.69%11.89%5.56%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
43
Neutral
C$1.26B-9.60-14.61%20.36%-186.10%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:WELL
WELL Health Technologies Corp
4.50
-0.84
-15.73%
TSE:CRRX
CareRx
3.68
1.79
94.71%
TSE:NLH
Nova Leap Health
0.30
-0.01
-3.23%
TSE:DR
Medical Facilities
14.55
0.56
4.03%
TSE:DNTL
dentalcorp Holdings
10.93
0.69
6.74%

WELL Health Technologies Corp Corporate Events

Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
WELL Health Technologies Achieves Record Q3-2025 Financial Results
Positive
Nov 6, 2025

WELL Health Technologies Corp reported record financial results for Q3-2025, with revenues reaching $364.6 million, a 56% increase from the previous year, driven by organic growth and acquisitions. The company achieved a record Adjusted EBITDA of $59.9 million, marking a 296% increase, and highlighted improvements in operational efficiency and patient visits in its Canadian clinics. WELLSTAR, a majority-owned subsidiary, secured $62 million in financing, reflecting strong market confidence and positioning it for future growth and an IPO.

The most recent analyst rating on (TSE:WELL) stock is a Hold with a C$6.00 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.

Business Operations and StrategyPrivate Placements and Financing
WELLSTAR Technologies Secures C$62 Million for Growth Ahead of Spinout
Positive
Oct 31, 2025

WELL Health Technologies Corp’s subsidiary, WELLSTAR Technologies, has announced a C$62 million equity placement to support its growth strategy ahead of a planned spinout. The financing, backed by prominent Canadian investors, is expected to close in December 2025 and will be used for AI innovation, acquisitions, and organic growth. This move highlights investor confidence in WELLSTAR’s performance and positions the company for a public listing in 2026, offering direct investment opportunities in a high-growth healthcare technology firm.

The most recent analyst rating on (TSE:WELL) stock is a Hold with a C$5.25 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.

Financial Disclosures
WELL Health Technologies to Release Q3 2025 Financial Results
Neutral
Oct 23, 2025

WELL Health Technologies Corp. announced it will release its Fiscal Third Quarter 2025 financial results on November 6, 2025. The company will hold a conference call and webcast on the same day to discuss the results, which could provide insights into its operational performance and market positioning.

The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$9.00 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
WELL Health Technologies Achieves Record Q2-2025 Results and Milestone Patient Visits
Positive
Aug 14, 2025

WELL Health Technologies Corp reported record financial results for Q2-2025, achieving a 57% increase in quarterly revenues to $356.7 million, driven by organic growth and acquisitions. The company also marked its first-ever quarter with over 1 million patient visits in Canada, reflecting a 38% year-over-year growth. WELL’s strategic investments in Canadian clinics and technology have led to improved provider productivity and significant milestones in financial metrics, including Adjusted EBITDA and net income. The inclusion of HEALWELL AI contributed $40.5 million to revenue, and the company is considering strategic alternatives for its U.S. assets to focus on core Canadian operations.

The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 08, 2025